-
- About PMI
-
Smoke-free approach
- Harm Reduction
- Absence of Combustion
- Nicotine
- Tar
- Tobacco Regulation
- Harmful Chemicals Measured
Smoke-free approachOffering smoke-free alternatives to adult smokers is a sensible, complementary addition to existing tobacco control strategies.Read More -
Research
- PMI’s Studies on Smoke-Free Products
- Our Findings
- PMI Publications Library
- Literature Reviews
- Independent Studies
- Investigator Initiated Studies (IIS)
- Facts and Figures on Our Smoke-Free Future
ResearchExplore our product assessment program, its results, and the publications where they are published. Find a wealth of independent research and expert reports.Read More -
Our Products
- Heated Tobacco Products
- E-cigarettes and Vaping Products
- Oral Nicotine Pouches
- Nicotine Salts Product
Our ProductsPMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.Read More -
News & Events
- Scientific Update Magazine
- Open Science Events
- News
- Conferences Calendar
News & EventsRead our most recent articles and catch up on our latest events and conference presentations.Read More - Contact Us
European Exposure Study
A European, Multi-centre Study to Determine the Exposure of Adult Smokers and Non-smokers to Cigarette Smoke Constituents
The current study was designed to determine the exposure of adult smokers and non-smokers to cigarette smoke constituents through evaluation of selected biomarkers of exposure.
Recruitment: Completed
Study Results: No Results Available
Enrollment: 1667
Study Type: Observational
Other IDs: SPA0403
Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)
Nicotine Pharmacokinetic Profile of the CHTP 1.1 M
Smoking Research Study
Accuracy of the smoking questionnaire
Effects of switching to the Tobacco Heating System 2.2 menthol, smoking abstinence, or continued cigarette smoking on biomarkers of exposure: A randomized, controlled, open-label, multicenter study in sequential confinement and ambulatory settings (Part 1)
Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.